drugset / Trial / NCT00526006

PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena

NCT00526006

Phase 4 Unknown Zealand University Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The acid secretion in the stomach seems to increase after withdrawal of min. 8 wks of treatment with a PPI (protonpump inhibitor) It is unknown if this acid rebound phenomenon is of clinical significance. In a doubleblinded and placebocontrolled study healthy volunteers are randomized to treatment with placebo or PPI + placebo. Gastrointestinal symptoms are scored once a week and.

Timeline

Start
2007-09
Primary completion
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg

Indications

No indication recorded.